Advaxis, Inc. Lead Product Candidate ADXS-HPV in Combination With PD-1 Antibody Significantly Improves Immune and Therapeutic Efficacy in Preclinical Study  
9/5/2013 10:50:25 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (OTCQB: ADXS) (“Advaxis” or the “Company”), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced the publication of preclinical research with ADXS-HPV, Advaxis’ Lm-LLO lead drug candidate, for the treatment of HPV-associated cancers in combination with PD-1 antibody. The research was conducted by Dr. Samir N. Khleif and his research team at the Georgia Regents University Cancer Center. Advaxis provided the Lm-LLO immunotherapies and partial research funding. The paper titled “Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy” by Drs. Mkrtichyan, Chong, Eid, Wallecha, Singh, Rothman, and Khleif, has been e-published in the Journal for Immunotherapy of Cancer.

Help employers find you! Check out all the jobs and post your resume.